|
At December 31, 1998, the Company was party to the following intercompany agreement with several of its affiliates: Apportionment of Expense Agreement Pursuant to the terms of an agreement effective January 1, 1982, ZHCA provides some or all of the business operations of its subsidiaries through the organization and staff of Zurich American Insurance Company in the following areas: investments, planning, auditing, management, taxes, actuarial, budgeting, legal, claims, loss control, accounting, data processing, underwriting, personnel, administration, and other functions. At December 31, 1998, the affiliated parties to this agreement were as follows: American Guarantee and Liability Insurance Company Zurich American Insurance Company of Illinois American Zurich Insurance Company Steadfast Insurance Company Atlas General Agency, Inc. Empire Fire and Marine Insurance Company Universal Underwriters, Inc. Maryland Casualty Company Zurich-American Brokerage. Zurich Global, Ltd. Vistar Risk Management Services F&D Holding Corporation Zurich Direct, Inc. Zurich Life Insurance Company of America Expenses are apportioned to each of the companies as follows: 1. Federal Income Taxes: Are apportioned pursuant to the tax sharing agreement. 2. Investment Expenses: Each company pays those investment expenses directly identifiable to its portfolio. Indirect expenses are allocated based on a study of weighted investment transactions or other generally accepted cost allocation methods. 3. Operating Expenses: Each company pays its own directly identifiable operating expenses. 4. Other Claim or Operating Expenses: Allocated in accordance with generally accepted practices of cost allocation.
DOSAGE AND ADMINISTRATION Care in the administration of doxorubicin will reduce the chance of perivenous infiltration see WARNINGS ; . It may also decrease the chance of local reactions such as urticaria and erythematous streaking. On intravenous administration of doxorubicin, extravasation may occur with or without an accompanying burning or stinging sensation, even if blood returns well on aspiration of the infusion needle. If any signs or symptoms of extravasation have occurred, the injection or infusion should be immediately terminated and restarted in another vein. If extravasation is suspected, intermittent application of ice to the site for 15 min. q.i.d. x 3 days may be useful. The benefit of local administration of drugs has not been clearly established. Because of the progressive nature of extravasation reactions, close observation and plastic surgery consultation is recommended. Blistering, ulceration and or persistent pain are indications for wide excision surgery, followed by split-thickness skin grafting. The most commonly used dose schedule when used as a single agent is 60 to mg m2 as a single intravenous injection administered at 21-day intervals. The lower dosage should be given to patients with inadequate marrow reserves due to old age, or prior therapy, or neoplastic marrow infiltration.
A Learning Experience in More Ways Than One Florida Basic Farm Training by Jonathan Austin From January 16 through January 22nd, Quality Certification Services Florida Organic Growers co-sponsored with IOIA our very first Organic Inspectors Training. As with everything in the organic industry, and life in general for that matter, the most impressive part was the people who were involved. Don't let anyone ever suggest to you that attending, teaching, or arranging such a training is easy. It is hard work involving long hours from everyone involved. I really must commend all of our attendees for their hard work and their patience with all of the goofs and snafus that inevitably occur in executing such a training for the first time. Our learning curve was as steep as theirs. Note to self: "An overhead transparency projector is useless without a stock of actual overhead transparencies." ; The instructors, John Burns and Rick Martinez also did a fantastic job of keeping people attentive and engaged for 12 hours a day, a great testament to John and Rick's knowledge, enthusiasm, and skill. And of course, Margaret and Lisa were our guardian angels, ready with that document that we neglected to ask for, or to steer us in the right direction when we inevitably went astray. To all who were involved, I offer my sincere thanks and admiration.
Had abnormally high baseline levels . 140 mg dl 3.62 mM for LDL-cholesterol, there were similar reductions at the end of the open-label study results not shown.
The novel bis-phenazine XR5944 MLN944 ; is an extremely potent cytotoxic agent both in vitro and in vivo 1 ; . Against a panel of human cell lines in vitro, the IC50 of XR5944 was 0.04 to 0.4 nmol L, and this potency translated well to human xenograft models in vivo where XR5944 induced complete tumor regression in the H69 small cell lung carcinoma model 1 ; . Although XR5944 originated from a program to generate dual topoisomerase I and II inhibitors 2 ; , recent data suggest that cell death is not mediated via topoisomerase inhibition, but the precise mechanism of action is still being elucidated. XR5944 has been reported to bind strongly and intercalate into DNA 2 ; and can stabilize topoisomerase-dependent cleavage complexes as visualized by electrophoresis using linearized, labeled plasmid DNA and purified topoisomerases I and II. XR5944 also induced cleavage complex formation for topoisomerases I, II, and II in human leukemic K562 cells visualized using the Trapped in Agarose DNA Immunostaining assay 3 ; . Although these observations suggested a topoisomerase-mediated mechanism for XR5944, the increase in enzyme-mediated DNA cleavage required relatively high concentrations of XR5944 and, in the K562 cells, long incubation times. Furthermore, data have been presented recently demonstrating a topoisomerase-independent mechanism of action for XR5944. In yeast models, the cytotoxicity of XR5944 was not dependent on the presence of either topoisomerase I or II and the potency was not attenuated in mutant strains unable to repair dsDNA breaks 4 ; . Cell cycle analysis also differentiated XR5944 from both topoisomerase I and II inhibitors, as XR5944 treatment induced a G1 and G2 arrest in contrast to the G2-M arrest noted with either doxorubicin a topoisomerase II inhibitor ; or camptothecin a topoisomerase I inhibitor; ref. 4 ; . Finally, functional genomic data have also differentiated XR5944 from known topoisomerase inhibitors. Transcript profiling of XR5944 in yeast cells indicated up-regulated expression of RNA polymerase subunits as well as genes involved in rRNA processing; importantly, DNA damage response genes seemed to be unaffected 4 ; . Previous in vitro studies showed that XR5944 is probably a substrate for both multidrug resistance MDR ; associated protein MRP ; and P-glycoprotein P-gp; ref. 1 ; , the product of the MDR1 gene. Although the potency of.
This integrated analysis does not include the phase 3, velcade plus doxil ® doxorubicin hcl liposome injection ; study and dronabinol.
Alfresa Pharma Corporation Graphic Packaging International, Inc. Raytheon Company SANDEN CORPORATION FUJI PHOTO FILM CO., LTD. Goss International Americas, Inc. The Nottingham Trent University Kolthoff & Co. Caradon Heating Europe B.V. Omron Corporation Entegris, Inc. Testo GmbH & Co. ALCATEL Amersham Health AS Bioniche Life Sciences Inc. Koninklijke Philips Electronics N.V. C. Stiefelmayer GmbH & Co SUN MICROSYSTEMS, INC. Diversified Dynamics Corporation RISO KAGAKU CORPORATION Meiji Seika Kaisha, Ltd. Assemblon N.V. Peugeot Citroen Automobiles SA SMS SCHLOEMANN-SIEMAG AKTIENGESELLSCHAFT.
Likely pathogens. However, the tissue concentrations at the site of infection may be more relevant for the effects of antibiotics Baldwin et al., 1990 ; . Consequently, it is important to clarify the distribution mechanism of GPFX in the lung. The possible mechanisms involved in the tissue accumulation of drugs are considered likely to be higher tissue uptake and or tissue binding, or lower efflux from the tissues. Various determining factors have been identified for the tissue distribution of certain types of drugs. For example, binding to the nuclei is involved in the tissue distribution of doxorubicin Terasaki et al., 1984 ; . The Kp values for vinca alkaloids, such as vincristine and vinblastine, correlate with the tissue tubulin concentration Wierzda et al., 1987, 1988 ; . Okumura et al. 1978, 1989 ; and Yoshida et al. 1987, 1989 ; reported specific common binding sites for basic drugs in the lung, the affinity for these sites being dependent on the lipid solubility of the drugs. Yata et al. 1990 ; and Nishiura et al. 1986, 1987, 1988 ; reported the involvement of phospholipids in the tissue distribution of basic drugs. Ishizaki et al. 1998a, b ; reported that some basic drugs, such as biperiden and trihexiphenidyl, are mainly distributed in the postnuclear fractions containing the acidic organelles e.g., lysosomes ; . Concerning the NQs, HSR-903 has been reported to be taken up by active transport into isolated rat lung cells Murata et al., 1999 ; , although the contribution of this uptake to their lung distribution has not yet been fully characterized. In the present study, to clarify the mechanism governing the distribution of GPFX to the lung, the uptake, binding, and efflux after intravenous administration of GPFX were evaluated in rats and dss.
Of the two agents, doxorubicin has a much lower limit of detection by analytical methods employed by the laboratories.
Serves to regulate proliferation and differentiation of epidermal cells 1, 2 ; . In human solid tumors, overactivation and or dysregulation of EGFR promotes tumor progression, including invasion, angiogenesis, metastasis, and treatment resistance with blocking apoptosis 36 ; . Because EGFR is important in epithelial tumor biology, EGFR-targeted cancer therapy has been developed 7 ; . Gefitinib ``Iressa'', ZD1839, AstraZeneca. Co., Macclesfield, United Kingdom ; is an orally active, selective EGFR tyrosine kinase inhibitor that blocks signal transduction pathways implicated in the proliferation and survival of cancer cells 8 ; . Although gefitinib combined with various cytotoxic agents, such as taxanes, platinums, and topotecan, has been reported to enhance cytotoxicity in vitro and in vivo, the exact enhancement mechanisms still remain undetermined 915 ; . Transporter proteins belonging to the ATP-binding cassette superfamily pump out drugs using the energy from ATP hydrolysis, leading to resistance of cancer cells against multiple anticancer drugs 16 ; . Among them, P-glycoprotein and the multidrug resistance protein family have been extensively investigated 16 ; . The breast cancer resistance protein BCRP ABCG2 ; of an ATP-binding cassette half-transporter was isolated from atypical multidrug-resistant MCF-7 human breast cancer cells selected with doxorubicin and verapamil 17 ; . BCRPoverexpressing cells show cross-resistance to mitoxantrone and DNA topoisomerase I inhibitors of topotecan and SN-38, suggesting strongly that BCRP plays an important role in acquiring resistance against these drugs 16, 18, 19 ; . We have already shown that BCRP efficiently transports SN-38 with a high affinity in vitro 20 ; . Interestingly, CI1033 of the HER family tyrosine kinase inhibitors was reported to enhance the cytotoxicity of topotecan and SN-38 through inhibition of BCRP-mediated drug efflux in cancer cells 21 ; . The HER family of receptors includes EGFR, HER-2, HER-3, and HER-4. Therefore, we hypothesized that gefitinib would reverse drug resistance in cancer cells overexpressing BCRP. Here, using plasma membrane vesicles, we report that gefitinib reverses BCRP-mediated resistance against topotecan, SN-38, and mitoxantrone through direct inhibition of BCRP in multidrug-resistant human small cell lung cancer and breast cancer cells and dulcolax.
Explanation for Choice B: While the patient has no complaints, she has developed anemia. Development of hypercalcemia, renal impairment, anemia, or bone disease would be an indication for treatment. Elevated IgA of 4.8 g dL would constitute Durie-Salmon stage II disease, generally accepted as indication for treatment. Dr. Jagannath's preferred answer is Choice D. ; Explanation for Choice C: This patient has no symptoms, although she has mild anemia; there is no lytic bone disease, and patient is on bisphosphonates. Therefore, correction of anemia could be done without initiation of treatment. However, if such a decision is made, the patient needs to be monitored more closely. Elevated IgA of 4.8 g dL would constitute Durie-Salmon stage II disease, generally accepted as an indication for treatment. The detection of chromosome 13 deletion on routine cytogenetics would indicate continued proliferation of myeloma clone, and there is no gain in allowing this patient to progress to an advanced stage myeloma. Dr. Jagannath's preferred answer is Choice D. ; Explanation for Choice D: This patient has developed anemia. Development of hypercalcemia, renal impairment, anemia or bone disease would be an indication for treatment. Elevated IgA of 4.8 g dL would constitute Durie-Salmon stage II disease, generally accepted as indication for treatment. In addition, the detection of chromosome 13 deletion on routine cytogenetics would indicate continued proliferation of myeloma clone. This is Dr. Jagannath's preferred answer for this patient. ; Question 3: Once decision to treat has been made for this patient, your choice of initial therapy would be: A. MP melphalan and prednisone ; B. VAD vincristine, doxorubicin, dexamethasone ; or DVD VAD except pegylated liposomal doxorubicin is substituted for standard doxorubicin ; C. Thalidomide and dexamethasone D. Bortezomib Velcade ; on clinical trial Explanation for choice A: Melphalan and prednisone is an oral, easy-to-administer and well-tolerated regimen that has been considered the standard of care for the treatment of multiple myeloma for the past 3 decades. The response rate is 50%-60%. The results of randomized clinical trials have shown melphalan and prednisone to be equivalent to other combination chemotherapies in terms of overall survival. Treatment with melphalan and prednisone is not recommended for patients eligible for autologous stem cell transplantation ASCT ; , due to the risk of damaging progenitor cells. Therefore, MP is now relegated to the management of patients over the age of 70 years. Dr. Jagannath's preferred answer is Choice D. ; Explanation for choice B: Infusional chemotherapy with vincristine, doxorubicin, and dexamethasone or VAD ; induces rapid tumor cytoreduction, with CR PR rate of 59% using ECOG Eastern Cooperative Oncology Group ; criteria; requires no dose modification for renal impairment; and is not toxic to stem cells. It has been the preferred induction therapy for patients under the age of seventy who were candidates for stem cell transplants. However, this treatment requires catheter placement. There is also hair loss and some neuropathy with exposure to vincristine. VDD has been shown to be equivalent to VAD, but it does not require catheter placement. Dr. Jagannath's preferred answer is Choice D.
Buy doxorubicin online
This interactive session will allow members of the audience to submit questions to senior leaders from the Center for Drug Evaluation and Research. The topics discussed will depend on the interests of the audience and duragesic.
Order doxorubicin
Although the fda does not believe it is a biogeneric, many others disagree and see it as the first step to opening the market.
Experimental studies have shown that exogenous n-3 polyunsaturated fatty acids PUFAs ; may sensitize tumor cells to anticancer drugs, in cell culture or in animal tumors Shao et al., 1995; Germain et al., 1999; Colas et al., 2004; Menendez et al., 2004; Menendez et al., 2005 ; . These effects of n-3 PUFA have been found to be inhibited by the presence of antioxidants Germain et al., 1998; Colas et al., 2004; Colas et al., 2005; Menendez et al., 2005 ; . Several mechanisms have been proposed to account for the effect of PUFAs in increasing anti-cancer drug efficacy. These include increase in drug transport across cell membrane Burns and North, 1986; Spector and Burns, 1987 ; , generation of free oxygen radicals and lipid peroxidation Das, 1999; Rose and Connolly, 1999; Stoll, 2002 ; . Among PUFAs, docosahexaenoic acid DHA, a long chain omega-3 polyunsaturated fatty acid ; was the most potent to enhance the cytotoxic effect of doxorubicin in MDA-MB-231 breast cancer cell line Germain et al., 1999 ; . Recently, we found that the DHA-induced increase in doxorubicin cytotoxicity was cell line-dependent and linked to oxidative stress Maheo et al., 2005 ; . Mitoxantrone MTX ; , an anthracenedione, has a spectrum of clinical activity similar to that of anthracyclines. Antineoplastic activity of anthracyclins and anthracenediones has been mainly attributed to topoisomerase II inhibition and to reactive oxygen species ROS ; production Gewirtz, 1999 ; . However MTX has been shown to generate free radicals to a much lesser degree than doxorubicin Novak and Kharasch, 1985 ; . Little is known about the effect of DHA on chemosensitivity of breast cancer cell lines to MTX. Supplementation of leukemia cells by DHA led to an increase in MTX uptake Burns et al., 1988a ; but no change in intracellular distribution of the drug was detected in subcellular fractions obtained by differential centrifugation and sucrose gradient separation after cellular disruption Burns et al., 1988b and echinacea.
50303 Phase III Randomized Study of R-CHOP versus Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas Rationale This is a phase III randomized comparison of rituximab R ; CHOP, the de facto standard for diffuse large B-cell lymphoma DLBCL ; , to dose-adjusted DA ; -EPOCH-R, a regimen developed from studies on drug schedule and resistance and pharmacokinetics. Importantly, this study will incorporate tumor microarray analysis using Affymetrix genome arrays in all patients to identify molecular mechanisms of drug resistance, develop molecular prognostic models, and to assess microarray tissue diagnosis. Retrospective microarray results with CHOP-based treatment in DLBCL have already identified that tumor proliferation and the Activated B-cell signature are the most important adverse molecular prognostic features. Results with DA-EPOCH show that it can abrogate tumor proliferation as an adverse prognostic factor, making the testing of DA-EPOCH a rational next step approach based on the microarray. Trial design This trial is available on the CTSU menu. Patients will be randomized to receive either R-CHOP or DA-EPOCH-R for 6 cycles. The primary objectives are to compare the eventfree survival of R-CHOP versus DA-EPOCH-R chemotherapy in untreated CD20 + DLBCL, and to develop a molecular predictor of outcome of R-CHOP and DA-EPOCH-R chemotherapy using molecular profiling. The secondary objectives are: 1 ; to compare the response rates, overall survival, and toxicity of R-CHOP and DA-EPOCH-R; 2 ; to define the pharmacogenomics of untreated DLBCL and correlate clinical parameters with molecular profiling; 3 ; to assess the use of molecular profiling for pathological diagnosis; and 4 ; to identify new therapeutic targets using molecular profiling. All patients must be offered participation in the correlative science substudy, CALGB 60405, Pharmacogenomics in CALGB 50303. Eligibility Eligible patients must have histologically documented de novo stage I or higher mediastinal DLBCL or any stage II, III, or IV DLBCL, and must have 1 of the following WHO histologic subtypes without evidence of indolent histological features in the tissue biopsy or bone marrow: 1 ; CD20 + DLBCL includes centroblastic; immunoblastic; T-cell histiocyte rich; and anaplastic 2 ; CD20 + mediastinal LBCL; 3 ; CD20 + intravascular LBCL. Patients should have had no prior cytotoxic chemotherapy or rituximab. Treatment plan Patients randomized to CHOP-R will receive rituximab 375 mg m2 IV infusion on day 1 prior to CHOP chemotherapy; cyclophosphamide 750 mg m2 IV day 1; doxorubicin 50 mg m2 IV day 1; vincristine 1.4 mg m2 IV day 1; and prednisone 40 mg m2 day PO on days 1-5. Filgrastim or pegfilgrastim is allowed.The cycle is repeated every 21 days for 6 cycles, and patients are restaged after cycles 4, 6. Patients randomized to DA-EPOCH-R will receive rituximab 375 mg m2 IV infusion on day 1 prior to EPOCH chemotherapy; dose level 1 ; doxorubicin 10 mg m2 day CIVI days 1-4; etoposide 50 mg m2 day CIVI days 1-4; vincristine 0.4 mg m2 day CIVI days 1-4; cyclophosphamide 750 mg m2 IV day 5; and prednisone 60 mg m2 PO on days 1-5. Filgrastim is required use of pegfilgrastim requires study chair approval ; . Doses of doxorubicin, etoposide and cyclophosphamide are increased 20% over the previous cycle if the neutrophil nadir is over 500 cells ul. The cycle is repeated every 21 days for 6 cycles and patients are restaged after cycles 4, 6. The study chairs are Wyndham H.Wilson, MD, PhD, National Cancer Institute, email: wilsonw mail.nih.gov, and Andrew D. Zelenetz, MD, PhD, Memorial Sloan-Kettering Cancer Center, email: a-zelenetz ski.mskcc.
A breakdown of reimbursable support services and special activities shown in table 4 b and efalizumab.
Order doxorubicin online
Bances, abnormal electrocardiographic changes, and acute, but reversible, reductions in left-ventricular ejection fraction LVEF ; .810 Generally, these symptoms occur within 24 hours of infusion, are self-limiting, and do not appear to increase the risk of future cardiac events.8 More often, however, the cardiotoxicity seen with conventional doxorubicin treatment manifests as a chronic complication, which ultimately results in congestive cardiomyopathy. Such toxicity has been shown to correlate with peak plasma doxorubicin concentrations, as well as with the lifetime cumulative dose administered.11, 12 Historically, cardiomyopathy has seldom been observed with cumulative doses of conventional doxorubicin below 450 mg m2; however, more recent evidence suggests that doxorubicin-induced congestive heart failure CHF ; may occur at lower doses and with greater frequency than previously noted.13, 14 Von Hoff and colleagues reported an incidence of conventional doxorubicin-induced CHF of approximately 3% at a cumulative dose of 400 mg m2, increasing to 7% at 550 mg m2 and to 18% at 700 mg m2.13 A recent retrospective analysis of data from 630 patients who had received conventional doxorubicin-containing regimens revealed that the risk of CHF began to increase with cumulative doses as low as 300 mg m2 Figure 2 ; .14 Overall, the estimated percentage of patients developing CHF was 5% at a cumulative conventional doxorubicin dose of 400 mg m2 and increased rapidly with higher dosage increments. Specifically, the incidence of CHF increased to 16% at a cumulative conventional doxorubicin dose of 500 mg m2, 26% with a cumulative dose of 550 mg m2, and 48% with cumulative doses of 700 mg m2.14 These incidences were markedly higher than those reported by Von Hoff and colleagues. One of the first steps taken toward reducing the risk of cardiotoxicity with.
14. Haisch M, Hering P, Fuss W, Fabinski W. A sensitive isotope selective non dispersive infrared spectrometer for 13CO2 and 12CO2 concentration measurements in breath samples. Isopenpraxis Environ Health Stud 1994; 30: 247-251. Koletzko S, Haisch M, Seeboth I, Braden B, Hengels K, Koletzko B, Hering P. Isotope selective non dispersive infrared spectrometry for detection of Helicobacter pylori infection with 13C-urea breath test. Lancet 1995; 345: 961-962. Dowlatabadi Bazaz R, Khalaj A, Beiki D, Eftekhari M , Al-Seyed Hosein MH, Khoshayand MR Microdose 14C urea breath test for the diagnosis of Helicobacter pylori: A survey in Iranian population. Daru 2005; 13 1 ; : 6-10 17. Rosner B. Fundamentals of biostatistics. Boston: PWS-Kent Publishing Company; 1990. 18. Gonzalez P, Galleguillos C, Massardo T, Rivera M, Morales A, Smok G, Moyano L, Pimentel C, Alay R, Otarola S. Could the [14C] urea breath test be proposed as a gold standard for detection of Helicobacter pylori infection? Med Sci Monit 2003; 9: CR363-368. 19. Wong WM, Wong BCY, Wong KW, Fung FMY, Lai KC, Hu WHC, Yuen ST, Leung SY, Lau GKK, Lai CL, Chan CK, Go R, Lam SK 13C-urea breath test without a test meal is highly accurate for the detection of Helicobacter pylori infection in Chinese. Aliment Pharmacol Ther 2000; 14: 1353-1358. Chua TS, Fock KM, Teo EK, Ng TM, Validation of 13C-urea breath test for diagnosis of Helicobacter pylori infection in the Singapore population. Singapore Med J 2002; 43 8 ; : 408-411. 21. Braden B, Schafer F, Caspary WF, Lembcke B. Nondispersive isotope-selective infrared spectroscopy: a new analytical method for 13C-urea breath tests. Scand J Gastroenterol 1996; 31 5 ; : 442-445 and eletriptan.
Lot 016 - POT. 6th Gen VG EX # CANNONTOWN LOUSAN DELLIA 5091941 Born : 1 SEP 06 Ear No: 261005091941 ; sire dam g.dam 3.dam 4.dam 5.dam BEVERLAKE LOUSON 659264 BXL ; ALH DANITA 7238496 VG88 ; REGANCREST BELWOOD DAWN ET 100950 VG86-2YR-USA ; SNOW-N DELLIAS DARLENE ET 4278068 EX94-USA-GMD ; SNOW-N DENISES DELLIA 1289580 EX95-2E-GMD ; SNOW-N DORYS DENISE EX-2E-GMD ; by ETAZON ADDISON EZA ; by WA-DEL CONVINCER EX94-GM by MAIZEFIELD BELLWOOD EX95-GM by TO-MAR BLACKSTAR EX-GM by WALKWAY CHIEF MARK VG-GM.
Page Number Important Phone Numbers When to call for help.1 Understanding Congestive Heart Failure What is congestive heart failure? .3 What causes congestive heart failure? .3-4 How blood moves through the heart .5 What are the symptoms of congestive heart failure?.7-8 What You Can Do to Take Care of Yourself The Basics .9-10 Medication Schedule.11 Daily Weight Diary .13 Directions from Your Healthcare Provider .15 Lifestyle Changes Activity .17 Exercise .17 Diet .18-19 Diagnosing Congestive Heart Failure .21-22 Treating Congestive Heart Failure Medications .23-25 Other treatment .26 Long-term outlook.26 Glossary .27 Reading List .29-31 Sodium Content of Foods Read the Label .33-34 Dining at Home .35-43 Dining Out--What to order and what to avoid .45-48 Fast Foods.49-57 and elidel.
|
ABBREVIATED PRESCRIBING INFORMATION for TAXOTERE docetaxel ; 20 or 80 mg TAXOTERE docetaxel ; concentrate for solution for infusion is available in single-dose vials containing 20 or 80 mg in 0.5 or 2.0 ml of polysorbate 80, respectively with a solvent vial 13% ethanol in water for injections ; . PHARMACOLOGICAL PROPERTIES: Docetaxel promotes the assembly of tubulin into stable microtubules and inhibits their disassembly. INDICATIONS: Locally advanced or metastatic breast cancer in combination with doxorubicin in patients who have not previously received cytotoxic therapy. Locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent. Locally advanced or metastatic nonsmall cell lung cancer NSCLC ; after failure of prior chemotherapy. DOSAGE: 75 mg m 2 in combination therapy with doxorubicin 50 mg m2 ; for breast cancer. 100 mg m 2 for breast cancer and 75 mg m 2 for NSCLC, as a one-hour infusion every three weeks. All patients must be pretreated with an oral corticosteroid for 3 days starting one day before each TAXOTERE administration. Dosage adjustments during treatment: TAXOTERE should be administered when the neutrophil count is 1, 500 cells mm3 In patients with either febrile neutropenia, neutrophil 500 cells mm3 for 7 days, severe or cumulative cutaneous reactions or severe neurosensory signs and or symptoms, the dose should be reduced by 25%. If these reactions continue, the dosage should either be decreased to 60 mg or treatment discontinued. No data are available in patients with hepatic impairment treated by docetaxel in combination. Dosage adjustments in patients with elevated liver function tests: Patients with elevated ALT and or AST 1.5 times the upper limit of the normal range ULN ; concurrent with increases in alkaline phosphatase 2.5 times the ULN, the recommended dose of TAXOTERE is 75 mg m2. In patients with serum bilirubin ULN and or ALT AST values 3.5 times the ULN associated with alkaline phosphatase 6 times the ULN, TAXOTERE should not be used unless strictly indicated. CONTRAINDICATIONS: Hypersensitivity reactions to docetaxel or polysorbate 80; Baseline neutrophil count of 1, 500 cells mnV; Severe liver impairment; Pregnancy or breast feeding. WARNINGS AND PRECAUTIONS: Haematology: Neutropenia is the most frequent adverse reaction and may require dosage reduction see Dosage adjustments ; . Frequent monitoring of complete blood counts is required in all patients receiving docetaxel. Severe hypersensitivity reactions require immediate discontinuation and appropriate therapy and should not be rechallenged. Minor hypersensitivity reactions do not require interruption of therapy. Cutaneous and CNS: Localised skin erythema or severe neurosensory.
Vincristine and doxorubicin are administered simultaneously, and continuously as an infusion for 4 days and eligard and doxorubicin.
Twenty-six patients with an average age of 58 range, 17-79 ; were treated with this regimen consisting of cyclophosphamide, vincristine, doxorubicin and dexamethasone.
| The breast in treatment of climacteric women Leifland K Mammografi avd, S: t Grans Sjukhus, Stockholm, Sweden karin.leifland stgoran Hormone replacement therapy HRT ; has been given to postmenopausal women for more than 30 years. A therapy boom took place in the beginning of the 1990s . The gynecologists have been very aware of the gynecological positive and negative effects of HRT, but only in recent years they have realised that HRT also affects the breast tissue. The mammography radiologists on the other hand have for more than a decade seen the increase in mammographic breast density caused by HRT, especially in the breast screening cohort in which women in the age group 40 to 74 are invited every other year to a mammography check up in the search for breast cancer. The Swedish Breast Cancer screening program initiated by the Swedish Board of Health and Welfare has reduced the breast cancer mortality by in general 20 - 30%. 80 - 150 women are invited every weekday per screening unit and 1 - 2 mammograms are taken of each breast. The only purpose of the screening program is to find breast cancers in an early stage and in a cost effective way. Breast density is the third strongest risk factor for breast cancer after sex and age. Various HRT regimes effect the breast density in different ways. Continuous combined HRT increase mammographic density in more than 50 %. Cyclic continuous combination HRT and oral estrogen-only therapy will increase the breast density in 20 % of the patients, while tibolone-only treatment only will increase the density in 5 %. The increase in mammographic density is apparent rapidly after only a few weeks use. It has been shown that continuous combined HRT not only results in a density increase but also increase the risk of breast cancer with almost 25 % increase in risk for each 5 year period of use. Several authors claim that the use of HRT leads to a decrease in the sensitivity of breast screening 64 - 65% compared to 77 - 80 % according to Kavanagh et al ; and that HRT-users have more false positive and more false negative screening results than non-users. The false negative results in more interval breast cancers. In my presentation I will show the impact of different HRT on the mammographic breast density and the difficulties that the mammography radiologists will have in interpretation when the breast density increases and elmiron.
Tesorus provide a turnkey solution that enables small companies to participate in pension and other employee savings plans. Participating companies' employees receive a booklet of 12 vouchers, each of which displays the amount of the employer contribution, the amount paid by the employee and the total amount invested in savings products. Whenever they choose to, employees send one or more Tesorus vouchers to Servepar, an equally owned joint venture with Natexis Banques Populaires.
Order doxorubicin online
Treatment with this dose of BR96-doxorubicin in combination with the MTD of paclitaxel was more efficacious than treatment with either agent alone and resulted in 67% durable CRs, 16% CRs, and 16% PRs. There was no evidence of toxicity no lethality, weight loss, or lethargy ; in rats treated with this combination regimen. BR96-Doxorubicin Increases the Population of Cells in G2-M. Studies with synchronized populations have demonstrated that cells are most sensitive to paclitaxel-induced apoptosis during the G0-G1 and G2-M transitions of the cell cycle 20 ; . In the studies described here, we evaluated whether changes in cell cycle distribution occurred as a consequence of exposure to BR96-doxorubicin. The cell cycle distribution following a 24-h exposure of L2987 lung carcinoma cells to BR96-doxorubicin 0.25 M BR96, 2 M doxorubicin ; , 2 M doxorubicin, 0.25 M BR96, or 0.25 M human IgG is shown in Fig. 4. Exposure to BR96-doxorubicin significantly P 0.002 ; increased the percentage of cells accumulating in G2-M 71.7 0.19% ; relative to untreated cells 15.24 1.40% ; or cells treated with human IgG 14.84 0.3% ; . The G0-G1 population was significantly P 0.001 ; reduced following treatment with BR96-doxorubicin, whereas the percentage of cells in S phase was not changed relative to control or IgG. Exposure to an equivalent concentration of doxorubicin resulted in a significant P 0.002 ; increase in the percentage of cells in G2-M, 29.73 0.65% ; relative to untreated or IgG-treated cells. This was accompanied by a significant P 0.002 ; decrease of cells in G0-G1 and a significant P 0.002 ; increase in the percentage of cells accumulating in S phase. In contrast, treatment with BR96 did not change cell cycle distribution relative to untreated control or an equivalent concentration of IgG. A similar change in cell cycle distribution resulting in an increased proportion of cells in the G2-M phase was also observed on RCA colon carcinoma a cells treated with BR96-doxorubicin data not shown.
|
Slamon, D. et al for the Breast Cancer International Research Group BCIRG ; A late breaking presentation ; BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel AC T ; with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab AC TH ; with docetaxel , carboplatin and trastuzumab TCH ; in HER2neu positive early breast cancer patients.
Doxorubicin hcl warning: doxorubicin hcl must be given slowly and directly into a vein iv ; through other intravenous iv ; fluids.
Finite element analysis FEA ; is a numerical method for solving engineering problems including structural analysis, heat transfer, fluid flow, mass transport, and electromagnetic potential. Development of the modern FEA method began in the 1940's through the work of Hrennikoff and McHenry. Their work and the work of others was not widely recognized due to the cumbersome mathematical calculations involved with the technique. This began to change with the development of digital computers in the 1950's. In the 1960's and 70's, the applications of FEA began to expand away from traditional structural analysis and the complexity of the problems solved with FEA increased with the availability of increasing computational power. Brekelmans et al. introduced FEA to the medical literature in 1972 in their study of the behavior of skeletal parts. Wolff established a relationship between the architecture of bone and its load bearing function as early as 1870, however, classic mathematical tools available for stress analysis were not very applicable to the irregular structural properties of bone. FEA was quickly recognized as the logical solution to this problem, due to its ability to evaluate stress in structures of complex shape, loading, and material properties Since this time, medical FEA application has grown exponentially. Although its primary medical use is in the field of orthopedic biomechanics, especially arthroplasty and fracture fixation, other varied applications include artificial heart valves, intraocular implants, tension on skin grafts, and recently, examining the mechanics of DNA supercoiling. THE FINITE ELEMENT METHOD FEA is a technique for predicting the response of structures and materials to environmental factors such as forces, heat and vibration. We will deal with forces in this description. When a structure is loaded, stresses are generated in the materials which compose the structure. The magnitudes and directions of these forces are dependent upon the shape of the structure, the material properties of the structure elasticity, homogeneity etc. ; , the magnitude of the load or loads, and where the load s ; are applied. The response is also dependent upon how the structure interacts with its environment; is it rigidly attached to a solid surface or is it allowed to slide? These interactions are called boundary conditions. So, to perform an analysis, four pieces of information must be available: geometry; material properties; loading conditions; and boundary conditions. A computer model of the structure is created using known geometry. Biological structures are very difficult to model using solid modeling software so other methods have been used such as three dimensional digitization and computed tomography three dimensional reconstruction. The model is then mathematically divided into a number of blocks elements ; which are connected to each other at specific points, usually corners, called nodes. This process is called meshing. Material properties are then assigned to the elements. Loading conditions are applied to the structure which must include the locations of the load, the direction of the load, and the magnitude of the load. Boundary conditions, which are usually displacements, are applied to the structure at the appropriate locations. The analysis software determines equations which describe the displacement of each node and all the equations are assembled into a stiffness matrix. The program then solves the matrix of simultaneous equations. Most software packages also include post-analysis programs to assist in interpretation of the data. This includes maximums, minimums, graphical full field stress and strain plots, displacement plots, deformation analysis and animation of deformation and strain as load is applied. INTERPRETATION It is important to remember that the solution obtained using FEA is approximate. The approximate solution converges on the exact solution for a given model as the mesh density or number of nodes elements ; approaches infinity. The accuracy of the model can be tested by increasing the mesh density an observing the change in results. This is called a convergency test. It is of perhaps greater importance to remember that the results of an analysis are only as good as the information used to construct the model. This is called the validity or the precision by which the mathematical descriptions of structural aspects loading conditions, model geometry, material properties, and boundary conditions ; mimic the real structure. Only accuracy can be checked with a convergency test, validity must be assessed by experimental verification. The initial application of FEA to biomechanics frequently produced results of questionable validity. This and dronabinol.
1. Young, R. C., Ozols, R. F., and Myers, C. E. The anthracycline antineoplastic drugs. N. Engl. J. Med., 305: 139 153, Von Hoff, D. D., Layard, M. W., Basa, P., Davis, H. L., Von Hoff, A. L., Rozencweig, M., and Muggia, F. M. Risk factors for doxorubicin induced congestive heart failure. Ann. Int. Med., 91: 710 717, Coley, H. M., Twentyman, P. R., and Workman, P. The efflux of anthracyclines in multidrug resistance in cancer treatment. Biochem. Pharmacol., 46: 13171326, 1993. Harris, A. L., and Hochhauser, D. Mechanisms of multidrug resistance in cancer treatment. Acta Oncol., 31: 205213, 1992. Duncan, R. Drug polymer conjugates: potential for improved chemotherapy. Anticancer Drugs, 3: 175210, 1992. Muggia, F. M. Doxorubicin-polymer conjugates: further demonstration of the concept of enhanced permeability and retention. Clin. Cancer Res., 5: 7 8, Duncan, R., Rejmanova, P., Kopecek, J., and Lloyd, J. B. Pinocytic uptake and intracellular degradation of N- 2-hydroxypropyl ; methacrylamide copolymers. A potential drug delivery system. Biochim Biophys Acta, 678: 143150, 1981. Noguchi, Y., Wu, J., Duncan, R., Strohalm, J., Ulbrich, K., Akaike, T., and Maeda, H. Early phase tumour accumulation of macromolecules: a greta difference in clearance rate between dox and normal tissues. Jpn. J. Cancer Res., 89: 307314, 1998. Yeung, T. K., Hopewell, J. W., Simmonds, R. H., Seymour, L. W., Duncan, R., Bellini, O., Grandi, M., Spreafico, F., Strohalm, J., and Ulbrich, K. Reduced cardiotoxicity of doxorubicin given in the form of N- 2-hydroxypropyl ; methacrylamide conjugates--an experimental study in the rat. Cancer Chemother. Pharmacol., 29: 105111, 1991. Minko, T., Koeckova, P., Pozharov, V., and Kopecek, J. HPMA copolymer bound Adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J, Controlled Release, 54: 223233, 1998. Duncan, R., Seymour, L. W., O'Hare, K. B., Flanagan, P. A., Wedge, S., Hume, I. C., Ulbrich, K., Strohalm, J., Subr, V., Spreafico, F., Grandi, M., Ripamonti, M., Farao, M., and Suarato, A. Preclinical evaluation of polymer-bound doxorubicin. J. Controlled Release, 19: 331346, 1992. Vasey, P. A., Kaye, S. B, Morrison, R, Twelves, C., Wilson, P., Duncan, R., Thomson, A., Murray, L., Hilditch, T. E., Murray, T., Burtles, S., Fraier, D, Frigerio, E., and Cassidy, J. Phase I clinical and pharmacokinetic study of PK1 [N- 2-hydroxypropyl ; methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-- drug polymer conjugates. Clin. Cancer Res., 5: 8394, 1999. Seymour, L. W., Ulbrich, K., Strohalm, J., Kopecek, J., and Duncan, R. The pharmacokinetics of polymer-bound Adriamycin. Biochem. Pharmacol., 39: 11251131, 1990. Seymour, L. W., Ulbrich, K., Steyger, P. S. Brereton, M. Subr, V., Strohalm, J., and Duncan, R. Tumour tropism and anti-cancer efficacy of polymer based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. Br. J. Cancer, 70: 636 641, Matsumura, Y., and Maeda, H. A new concept for macromolecular therapeutics in cancer therapy: mechanisms of tumoritropic accumula.
The insurers use a modified version of the ASC Grouping system that was developed by the Centers for Medicare and Medicaid Services CMS ; to pay for facility services in an ASC. Refer to Chapter 296-23B WAC in the Medical Aid Rules and the Facility Services section for more information.
Reversing the sequence of administration of doxorubicin and paclitaxel in the d.
A recent study showed that substituting doxil for doxorubicin in a regimen similar to vad dvd ; resulted in an improved toxicity profile and similar efficacy.
4 cycles - CMF x 4 cycles ; , and all patients chemotherapy for ABC with doxorubicin 50 mg m2 cycle + Taxol 175 mg m2 cycle every 3 weeks median number of 5 cycles patient, with a ORR of 72% ; . Response and survival CR was observed in 3 out of 29 patients 10%, 95% CI: 2%-27% ; , PR was observed in 11 38%, 95% CI: 21%58% ; for an ORR of 48% 95% CI: 29%-67% ; . There were also eight patients with SD 28% ; with a mean duration of 5 + months range 3 + -9 ; , and seven with PD 24% ; . The mean duration of CR and PR were 11 + range 4 + -18 ; and 9.5 + range 4 + -15 ; months, respectively. SD lasted a mean of 5 + months range 3 + -9 ; . After a mean follow-up of 9.25 months, median OS has not yet been reached since only one-third of the patients have died to date. Mean OS was 15.1 + months for CR patients range 6 + -21 ; , 10.2 + months for PR range 4 + 15 8.3 + for SD range 3 + -10 + ; , and 5.8 + for PD range 3-8 ; . Overall mean TTP and OS for all patients were 6.8 + months and 9.2 + months, respectively. Toxicity Enrolled patients received a total of 145 cycles with a mean of 5 cycles patients range 2-10 ; . Leukopenia was the most frequent and severe adverse effect: 18 of 29 patients 48% ; experienced grade 3 leukopenia without episodes of neutropenic fever. Thrombocytopenia was.
Department of Pharmaceutical and Biological Chemistry, The School of Pharmacy, University of London, London WC1N 1AX, United Kingdom [K. P., L. H. P.]; Department of Pharmacy, De Montfort University, Leicester LE1 9BH, United Kingdom [Z. P., P. T. S.]; Cancer Research UK Department of Medical Oncology, University of Glasgow, Glasgow G61 1BD, United Kingdom [J. A. P.]; and School of Cell and Molecular Biosciences, The Medical School, University of Newcastle upon Tyne, Newcastle upon Tyne NE2 4HH, United Kingdom [E. W., C. A. A.].
The trend to outsource fleets, as previously discussed, is evidenced by the growth in our own fleet over the last 12 years, from 11, 250 vehicles to 65, 300 vehicles at the end of April 2007. This fleet growth also demonstrates the robust nature of our business and its ability to grow through differing economic climates, an area we will explain in more detail later in the presentation.
|
